Special Issue "Emerging Cellular Therapies: T Cells and Beyond"
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 31 December 2018
Prof. Dr. Stephen Todryk
Cellular Therapies are fast becoming a viable option for the treatment of numerous diseases, due to the progress of technologies that enhance capabilities and reduce costs. They are typically used only when standard treatments have failed, since they are intensive in terms of skilled labour, reagents, and facilities; are often tailored or patient-specific; and, thus, remain expensive and limited in availability. This is in sharp contrast to off-the-shelf drugs. Therapies that have their basis in immune cells benefit from the potency of such cells, together with a mechanistic understanding of their often-complex action. Immunologists have always recognized the key role of T cells in health and disease. Their importance clinically is highlighted when they are absent or dysfunctional, such as in certain primary (genetic) or secondary (induced) immunodeficiencies, where viral infections predominate. Less obvious is their beneficial role as effector T cells in anti-cancer immunity, and their role as regulatory T cells in ameliorating inflammatory immune responses when not needed, such as in autoimmunity, transplantation, cancer therapy (graft vs host with haematopoietic stem cells), and allergy. Current T cell therapies involve manipulation of T cells in all these contexts, mainly ex-vivo, using a range of technological approaches, and are at various stages of clinical development. This Special Issue of Cells aims to highlight these approaches and applications, explain their technical and mechanistic bases, and update their current status and efficacy. Future paths that such “Cell Therapies” will take shall also be discussed.Prof. Dr. Stephen Todryk
Dr. Agnieszka Jozwik
Dr. Julian de Havilland
Dr. Joanna Hester
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- T cell therapy
- adoptive transfer
- anti-viral immunity
- regulatory T cells
- anti-tumour immunity
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Author: Mehmet Asim Bilen
Abstract: Genitourinary (GU) cancers are neoplasms of the genitourinary tract, which include renal, bladder, prostate, penile, testicular, and others urothelial in origin. Treatment for these cancers have traditionally been limited to surgery, radiation, and systemic treatment such as chemotherapy or immunotherapy, yet the treatment paradigm has been changing. Cellular therapies such as chimeric antigen receptor-T cells (CAR-T), stem cell transplantation, and other genomic interventions have shown great promise in the treatment of hematological malignancies. However, the results concerning the applicability of these measures to solid tumors like GU cancers have not yet been fully elucidated. In this Review, we aim to highlight existing and emerging cellular therapies, such as CAR-T, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, stem cell transplantation, oncolytic virus and dendritic cell vaccinations, and other immune regulators currently employed by researchers to treat GU cancers. Even though these therapies warrant further expansion and investigation, they already show great promise in the treatment regimen of these malignancies.